These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31308715)

  • 1. Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus.
    Toh ZQ; Kosasih J; Russell FM; Garland SM; Mulholland EK; Licciardi PV
    Infect Drug Resist; 2019; 12():1951-1967. PubMed ID: 31308715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.
    Van Damme P; Meijer CJLM; Kieninger D; Schuyleman A; Thomas S; Luxembourg A; Baudin M
    Vaccine; 2016 Jul; 34(35):4205-4212. PubMed ID: 27354258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the benefits and potential issues of the nonavalent HPV vaccine.
    Mariani L; Preti M; Cristoforoni P; Stigliano CM; Perino A
    Int J Gynaecol Obstet; 2017 Mar; 136(3):258-265. PubMed ID: 28087890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence.
    Signorelli C; Odone A; Ciorba V; Cella P; Audisio RA; Lombardi A; Mariani L; Mennini FS; Pecorelli S; Rezza G; Zuccotti GV; Peracino A
    Epidemiol Infect; 2017 Jul; 145(10):1962-1982. PubMed ID: 28446260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon.
    Chatterjee A
    Expert Rev Vaccines; 2014 Nov; 13(11):1279-90. PubMed ID: 25256262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on the 9-valent HPV vaccine.
    Lopalco PL
    Drug Des Devel Ther; 2017; 11():35-44. PubMed ID: 28053505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.
    Giuliano AR; Joura EA; Garland SM; Huh WK; Iversen OE; Kjaer SK; Ferenczy A; Kurman RJ; Ronnett BM; Stoler MH; Bautista OM; Moeller E; Ritter M; Shields C; Luxembourg A
    Gynecol Oncol; 2019 Jul; 154(1):110-117. PubMed ID: 30982556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine.
    López N; Torné A; Franco A; San-Martin M; Viayna E; Barrull C; Perulero N
    Infect Agent Cancer; 2018; 13():15. PubMed ID: 29743937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
    Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
    Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
    Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
    Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine.
    Bryan JT; Buckland B; Hammond J; Jansen KU
    Curr Opin Chem Biol; 2016 Jun; 32():34-47. PubMed ID: 26994695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
    Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
    Vaccine; 2018 Nov; 36(46):7017-7024. PubMed ID: 30314913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
    Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
    BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 9-Valent human papillomavirus vaccine: a review of the clinical development program.
    Luxembourg A; Moeller E
    Expert Rev Vaccines; 2017 Nov; 16(11):1119-1139. PubMed ID: 28956458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
    Luxembourg A; Bautista O; Moeller E; Ritter M; Chen J
    Contemp Clin Trials; 2015 May; 42():18-25. PubMed ID: 25749310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.
    Petry KU; Bollaerts K; Bonanni P; Stanley M; Drury R; Joura E; Kjaer SK; Meijer CJLM; Riethmuller D; Soubeyrand B; Van Damme P; Bosch X
    Hum Vaccin Immunother; 2018 Jul; 14(7):1800-1806. PubMed ID: 29553886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine.
    Chesson HW; Laprise JF; Brisson M; Markowitz LE
    J Infect Dis; 2016 Jun; 213(11):1694-700. PubMed ID: 26908738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine.
    Guevara A; Cabello R; Woelber L; Moreira ED; Joura E; Reich O; Shields C; Ellison MC; Joshi A; Luxembourg A
    Vaccine; 2017 Sep; 35(37):5050-5057. PubMed ID: 28789851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.